US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties

A NEW version of a bill that would restrict US business with certain Chinese biotechnology companies including WuXi AppTec and BGI would give US companies until 2032 to end work with the firms, extending the amount of time to find new partners.

The latest Biosecure Act also adds WuXi Biologics to a list of biotech companies of concern, according to a copy seen by Reuters. The other companies on the list are BGI, MGI, Complete Genomics and WuXi AppTec.

The revised bill will be introduced on Friday (May 10) and a US House of Representatives committee is expected to decide next week whether to move the bill forward, according to a House Committee on Oversight and Accountability spokesperson.

The committee markup, expected Wednesday, is a procedural step in the process to the bill’s possibly becoming law. A similar Senate bill was approved by a committee there in March.

The bills are designed to keep Americans’ personal health and genetic information from foreign adversaries.

A spokesperson for WuXi Biologics said they had not yet seen the revised bill and could not comment. The other companies listed did not immediately respond to requests for comment.

SEE ALSO

Biden’s plan to hit China with more tariffs is mostly symbolic

Chinese companies hit with US trade restrictions over spy balloon incident

US eyes curbs on China’s access to AI software behind apps like ChatGPT

US-China cooperation remains possible

The US-China tech ‘war’ in perspective

US automakers win extension on use of Chinese graphite in EV tax credits

More

Asean Intelligence

Get insights into businesses across South-east Asia

Get the free report

The latest bill “highlights a key vulnerability in our global supply chain and importantly provides a reasonable timeframe for companies to decouple their reliance on China-based biomanufacturing,” John Crowley, president of BIO, an industry association, said in a statement. REUTERS